Compare Abeona Therapeutics Inc (ABEO) vs Materials Select Sector SPDR Fund (XLB) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Materials Select Sector SPDR Fund — how do they compare? Abeona Therapeutics Inc trades at $6.73 (market cap $373.32M), while Materials Select Sector SPDR Fund trades at $50.12. The key difference: Abeona Therapeutics Inc is trading nearer its 52-week high, Materials Select Sector SPDR Fund nearer its low. Which is the better fit depends on your goals.
| ABEO | XLB | |
|---|---|---|
Market Cap | $373.32M | — |
Sector | Health | — |
52-Week High | $7.23 | $53.62 |
52-Week Low | $4.17 | $42.23 |
Enterprise Value | $228.22M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
XLB, the State Street Materials Select Sector SPDR ETF, trades at $51.98, down slightly by 0.06% today. Technical indicators show a bullish trend with strong moving average support, while oscillators are neutral. The ETF, which provides broad exposure to the U.S. materials sector, lacks disclosed fundamental ratios like P/E and P/S in the provided data. Recent news highlights sector interest, with family offices investing $4.8 billion in materials as of May 23, 2026 (Barron's).
The outlook for XLB is supported by sector rotation into materials amid geopolitical shifts and earnings growth potential, but risks include sensitivity to macroeconomic factors and inflation. Analyst sentiment is mixed, with some viewing valuations as less compelling after recent gains. The ETF's performance will hinge on broader industrial and economic trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Materials Select Sector SPDR Fund
In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes securities of companies from the following industries: chemicals; metals and mining; paper and forest products; containers and packaging; and construction materials. The fund is non-diversified.
Read more on XLB →
